Sugi Predict

Sugi Predict / Compounds / SCHEMBL2555596

SCHEMBL2555596

SCHEMBL2555596

O=C(O)Nc1cccc2ccc3cc4ccccc4cc3c12

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 7/20 0.47
▸ ALDH1A1 P00352 5/20 0.47
▸ MAPT P10636 5/20 0.47
▸ MEN1 O00255 4/20 0.47
▸ KMT2A Q03164 4/20 0.47
▸ GAA P10253 3/20 0.47
▸ SMN1; SMN2 Q16637 1/20 0.47
▸ HDAC1 Q13547 1/20 0.45
▸ HDAC7 Q8WUI4 1/20 0.45
▸ HDAC8 Q9BY41 1/20 0.45
▸ HDAC6 Q9UBN7 1/20 0.45
▸ TRPV1 Q8NER1 3/20 0.43
▸ CYP1A2 P05177 3/20 0.41
▸ NPC1 O15118 3/20 0.41
▸ RAB9A P51151 3/20 0.41
▸ CYP2C19 P33261 2/20 0.41
▸ CYP3A4 P08684 1/20 0.41
▸ CYP2D6 P10635 1/20 0.41
▸ CYP2C9 P11712 1/20 0.41
▸ HPGD P15428 3/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31310497 0.87 KDM4E (0.57) KDM4EALDH1A1MAPTMEN1KMT2A
SCHEMBL8655906 0.86 KDM4E (0.62) KDM4EALDH1A1MAPTMEN1KMT2A
SCHEMBL2555495 0.85 KDM4E (0.57) KDM4EALDH1A1MAPTMEN1KMT2A
SCHEMBL2555605 0.85 KDM4E (0.57) KDM4EALDH1A1MAPTMEN1KMT2A
SCHEMBL2552495 0.84 KDM4E (0.55) KDM4EALDH1A1MAPTMEN1KMT2A
SCHEMBL31206278 0.79 ALDH1A1 (0.77) KDM4EALDH1A1MAPTMEN1KMT2A
SCHEMBL9979277 0.78 ALDH1A1 (0.45) KDM4EALDH1A1MAPTMEN1KMT2A
SCHEMBL15845110 0.77 ALDH1A1 (0.55) KDM4EALDH1A1MAPTMEN1KMT2A
SCHEMBL16794736 0.76 ALDH1A1 (0.45) KDM4EALDH1A1MAPTMEN1KMT2A
SCHEMBL31597534 0.76 ALDH1A1 (0.45) KDM4EALDH1A1MAPTMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8999942-B2 Polyol modified aminoglycoside-lipid conjugates UNIVERSITY OF MANITOBA (CA) 2015-04-07 — — US disclosed
US-20130157969-A1 POLYOL MODIFIED AMINOGLYCOSIDE-LIPID CONJUGATES UNIVERSITY OF MANITOBA (CA) 2013-06-20 — — US disclosed
EP-2556079-A2 POLYOL MODIFIED AMINOGLYCOSIDE-LIPID CONJUGATES University Of Manitoba (CA) 2013-02-13 — — EP disclosed
WO-2011124986-A2 POLYOL MODIFIED AMINOGLYCOSIDE-LIPID CONJUGATES UNIVERSITY OF MANITOBA (CA) 2011-10-13 — — WO disclosed
US-7618949-B2 Drug-eluting stents coated with P2Y12 receptor antagonist compound INSPIRE PHARMACEUTICALS, INC. (US) 2009-11-17 — — US disclosed
US-20080287671-A1 DRUG-ELUTING STENTS COATED WITH P2Y12 RECEPTOR ANTAGONIST COMPOUND BOYER JOSE L 2008-11-20 — — US disclosed
US-7452870-B2 Drug-eluting stents coated with P2Y12 receptor antagonist compound INSPIRE PHARMACEUTICALS, INC. (US) 2008-11-18 — — US disclosed
EP-1942910-A2 DRUG-ELUTING STENTS COATED WITH P2Y12 RECEPTOR ANTAGONIST COMPOUND Inspire Pharmaceuticals, Inc. (US) 2008-07-16 — — EP disclosed
WO-2007056213-A2 DRUG-ELUTING STENTS COATED WITH P2Y12 RECEPTOR ANTAGONIST COMPOUND INSPIRE PHARMACEUTICALS, INC. (US) 2007-05-18 — — WO disclosed
EP-1758915-A2 COMPOSITION AND METHOD FOR INHIBITING PLATELET AGGREGATION Inspire Pharmaceuticals, Inc. (US) 2007-03-07 — — EP disclosed
US-7132408-B2 Composition and method for inhibiting platelet aggregation INSPIRE PHARMACEUTICALS, INC. (US) 2006-11-07 — — US disclosed
US-7101860-B2 Composition and method for inhibiting platelet aggregation INSPIRE PHARMACEUTICALS, INC. (US) 2006-09-05 — — US disclosed
US-20060122143-A1 Drug-eluting stents coated with P2Y12 receptor antagonist compound INSPIRE PHARMACEUTICALS, INC. 2006-06-08 — — US disclosed
WO-2005097814-A2 COMPOSITION AND METHOD FOR INHIBITING PLATELET AGGREGATION INSPIRE PHARMACEUTICALS, INC. (US) 2005-10-20 — — WO disclosed
US-20040220133-A1 Composition and method for inhibiting platelet aggregation INSPIRE PHARMACEUTICALS, INC. 2004-11-04 — — US disclosed
EP-1311525-A2 COMPOSITION AND METHOD FOR INHIBITING PLATELET AGGREGATION Inspire Pharmaceuticals, Inc. (US) 2003-05-21 — — EP disclosed
US-20020052337-A1 Composition and method for inhibiting platelet aggregation NORTH CAROLINA, UNIVERSITY OF 2002-05-02 — — US disclosed
WO-2002016381-A2 COMPOSITION AND METHOD FOR INHIBITING PLATELET AGGREGATION INSPIRE PHARMACEUTICALS, INC. (US) 2002-02-28 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060122143-A1 Drug-eluting stents coated with P2Y12 receptor antagonist compound P2RY12, P2RY11, P2RY13 KDM4E 3693/4885ALDH1A1 4375/4885MAPT 3285/4885
US-20040220133-A1 Composition and method for inhibiting platelet aggregation P2RY11, P2RY12, P2RY13 KDM4E 4400/4885ALDH1A1 3983/4885MAPT 4639/4885
US-20130157969-A1 POLYOL MODIFIED AMINOGLYCOSIDE-LIPID CONJUGATES AADAC, DDOST, AARS1 KDM4E 2382/4885ALDH1A1 3346/4885MAPT 4474/4885
US-20020052337-A1 Composition and method for inhibiting platelet aggregation P2RY11, P2RY12, P2RY13 KDM4E 4661/4885ALDH1A1 3933/4885MAPT 4706/4885
US-20080287671-A1 DRUG-ELUTING STENTS COATED WITH P2Y12 RECEPTOR ANTAGONIST COMPOUND P2RY12, P2RY11, P2RY13 KDM4E 3693/4885ALDH1A1 4375/4885MAPT 3285/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.